EP 4262765 A1 20231025 - USE OF BACTERIORUBERINS AND GLYCOSYL DERIVATIVES THEREOF TO PREVENT AND TREAT DISEASES INVOLVING DYSREGULATED PROTEIN AGGREGATION, SUCH AS NEURODEGENERATIVE DISEASES
Title (en)
USE OF BACTERIORUBERINS AND GLYCOSYL DERIVATIVES THEREOF TO PREVENT AND TREAT DISEASES INVOLVING DYSREGULATED PROTEIN AGGREGATION, SUCH AS NEURODEGENERATIVE DISEASES
Title (de)
VERWENDUNG VON BACTERIORUBINEN UND GLYCOSYLDERIVATEN DAVON ZUR VORBEUGUNG UND BEHANDLUNG VON ERKRANKUNGEN MIT DYSREGULIERTER PROTEINAGGREGATION WIE NEURODEGENERATIVEN ERKRANKUNGEN
Title (fr)
UTILISATION DES BACTÉRIORUBÉRINES ET LEURS DÉRIVÉS GLYCOSYLÉS POUR PRÉVENIR ET TRAITER LES MALADIES IMPLIQUANT UNE DÉRÉGULATION DE L'AGRÉGATION DES PROTÉINES, COMME LES MALADIES NEURODÉGÉNÉRATIVES
Publication
Application
Priority
- FR 2013390 A 20201216
- EP 2021086302 W 20211216
Abstract (en)
[origin: CA3202415A1] The invention concerns a composition comprising at least one bacterioruberin, preferably in the glycosylated form, optionally as a mixture with different forms of glycosylated bacterioruberins, or an extract comprising it, for its use in a method for the treatment or prevention of a disease involving a deregulation in protein aggregation such as a degenerative disease, for example, advantageously a neurodegenerative disease, fibrosis, advantageously pulmonary fibrosis, or diabetes. The invention also concerns a bacterioruberin, preferably in the glycosylated form, optionally as a mixture with different forms of glycosylated bacterioruberins, or an extract comprising it, for its use in a method for the treatment or prevention of a disease involving a deregulation in protein aggregation, and a method for the treatment or prevention of a degenerative disease.
IPC 8 full level
A61K 31/045 (2006.01); A61K 31/202 (2006.01); A61P 3/10 (2006.01); A61P 9/10 (2006.01); A61P 11/00 (2006.01); A61P 25/28 (2006.01); A61P 27/02 (2006.01)
CPC (source: EP)
A61K 31/045 (2013.01); A61K 31/202 (2013.01); A61P 3/10 (2017.12); A61P 9/10 (2017.12); A61P 11/00 (2017.12); A61P 25/28 (2017.12); A61P 27/02 (2017.12)
Citation (search report)
See references of WO 2022129407A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
Designated validation state (EPC)
KH MA MD TN
DOCDB simple family (publication)
FR 3117339 A1 20220617; CA 3202415 A1 20220623; CN 117500485 A 20240202; EP 4262765 A1 20231025; JP 2024502203 A 20240117; WO 2022129407 A1 20220623
DOCDB simple family (application)
FR 2013390 A 20201216; CA 3202415 A 20211216; CN 202180093923 A 20211216; EP 2021086302 W 20211216; EP 21823624 A 20211216; JP 2023561430 A 20211216